Your browser is no longer supported. Please, upgrade your browser.
Settings
BOLD Audentes Therapeutics, Inc. daily Stock Chart
BOLD [NASD]
Audentes Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.99 Insider Own7.30% Shs Outstand45.86M Perf Week-0.03%
Market Cap2.75B Forward P/E- EPS next Y-4.24 Insider Trans-1.66% Shs Float36.99M Perf Month1.01%
Income- PEG- EPS next Q-1.04 Inst Own- Short Float4.59% Perf Quarter118.79%
Sales- P/S- EPS this Y-22.60% Inst Trans- Short Ratio1.30 Perf Half Y66.77%
Book/sh8.38 P/B7.15 EPS next Y-1.70% ROA- Target Price58.75 Perf Year141.62%
Cash/sh- P/C- EPS next 5Y13.20% ROE- 52W Range22.00 - 60.00 Perf YTD0.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.05% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low172.59% ATR0.14
Employees207 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)90.38 Volatility0.04% 0.23%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.68 Prev Close59.98
ShortableNo LT Debt/Eq- EarningsFeb 06 AMC Payout- Avg Volume1.30M Price59.97
Recom2.90 SMA200.32% SMA5029.70% SMA20058.94% Volume2,152,319 Change-0.02%
Dec-06-19Downgrade JP Morgan Overweight → Neutral
Dec-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Dec-04-19Downgrade Chardan Capital Markets Buy → Neutral
Dec-03-19Upgrade Robert W. Baird Underperform → Neutral
Dec-03-19Upgrade Citigroup Sell → Neutral
Dec-03-19Downgrade Wedbush Outperform → Neutral
Dec-03-19Downgrade Raymond James Outperform → Mkt Perform
Dec-03-19Downgrade Piper Jaffray Overweight → Neutral
Dec-03-19Downgrade Mizuho Buy → Neutral
Dec-03-19Downgrade H.C. Wainwright Buy → Neutral
Dec-03-19Downgrade Guggenheim Buy → Neutral
Dec-03-19Downgrade BMO Capital Markets Outperform → Market Perform
Nov-19-19Upgrade Evercore ISI In-line → Outperform $40
Oct-03-19Initiated Robert W. Baird Underperform $10
Apr-26-19Reiterated H.C. Wainwright Buy $44 → $48
Apr-26-19Downgrade Citigroup Neutral → Sell $28 → $32
Feb-25-19Upgrade Chardan Capital Markets Neutral → Buy $35 → $40
Jan-11-19Upgrade Guggenheim Neutral → Buy
Nov-26-18Initiated JP Morgan Overweight $35
Nov-07-18Reiterated B. Riley FBR Sell $20 → $21
Jan-12-20 05:38PM  2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD) Insider Monkey
Jan-10-20 06:08PM  AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down Zacks
Jan-09-20 09:48AM  Agenus Initiates Phase I Study on Oncology Candidate AGEN1223 Zacks
Jan-03-20 01:00PM  STOCKHOLDER ALERT: Monteverde & Associates PC Remind Investors of its Ongoing Investigation Regarding the Acquisition ACCESSWIRE
Jan-02-20 06:30PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: CBPX, BOLD, THOR ACCESSWIRE
Dec-31-19 05:22PM  Big exec payouts, lawsuits mark gene therapy company's $3.1 billion merger deal American City Business Journals
12:00PM  SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Acquisition ACCESSWIRE
Dec-30-19 10:09AM  Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline Zacks
06:48AM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR ACCESSWIRE
Dec-27-19 04:30PM  STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Inquiry Regarding the Acquisition ACCESSWIRE
Dec-26-19 11:45PM  Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million Reuters
Dec-23-19 06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR ACCESSWIRE
10:11AM  Sarepta Signs Gene Therapy Agreement With Roche for $1.15B Zacks
09:00AM  LOGM, ARQL, TIF, and BOLD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
Dec-21-19 11:44AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders BOLD, INST, THOR GlobeNewswire
Dec-19-19 11:15AM  INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger ACCESSWIRE
Dec-18-19 06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR ACCESSWIRE
11:15AM  READ NOW: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Transaction ACCESSWIRE
Dec-17-19 06:50PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, KEM ACCESSWIRE
02:00PM  INVESTOR ALERT: Monteverde & Associates PC Continues its Investigation Regarding the Recent Merger ACCESSWIRE
Dec-16-19 07:30PM  TECD, TIF, BOLD, and WLH SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, KEM ACCESSWIRE
02:42PM  AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm Business Wire
11:15AM  SHAREHOLDER ALERT: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Merger ACCESSWIRE
11:00AM  MERGER ALERT - BOLD and TCBI: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
08:00AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders BOLD, AKS, INST, THOR GlobeNewswire
Dec-15-19 07:06PM  Theres more upside for biotech even after 24% gains in two months MarketWatch
Dec-13-19 04:15PM  URGENT NEWS: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger ACCESSWIRE
12:10PM  MERGER ALERT - BOLD and TCBI: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
08:55AM  Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
Dec-11-19 03:00PM  SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Merger ACCESSWIRE
Dec-10-19 09:30PM  BOLD, MDCO, AYR, and PEGI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
06:40PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Audentes Therapeutics, Inc. - (NasdaqGS: BOLD) ACCESSWIRE
04:35PM  STOCKHOLDER ALERT: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Acquisition ACCESSWIRE
11:51AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders INST, AKS, BOLD, SORL GlobeNewswire
Dec-09-19 01:45PM  MERGER ALERT - BOLD and INST: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
Dec-06-19 08:03PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLD PR Newswire
11:33AM  Hedge Funds Are Souring On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
02:12AM  Astellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade Moody's
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
09:37AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-04-19 10:15AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Audentes Therapeutics, Inc. to Astellas Pharma Inc. is Fair to Shareholders ACCESSWIRE
09:30AM  Company News for Dec 4, 2019 Zacks
07:06AM  The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 07:13PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc. PR Newswire +105.98%
04:22PM  This Gene Therapy Stock Just Netted A $3 Billion Bid Who's Next? Investor's Business Daily
12:37PM  Gene Therapy M&A Appetite Provides Lift After Audentes Deal Bloomberg
11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga
11:35AM  AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm PR Newswire
11:11AM  Astellas $3 billion gene therapy deal steadies investors after stalled Roche acquisition MarketWatch
11:03AM  Gene Therapies Get a $3 Billion Vote of Confidence Bloomberg
10:49AM  Japan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash Benzinga
09:37AM  Breakthrough gene therapy company snared by Japanese biopharma for $3 billion American City Business Journals
09:31AM  Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals. Barrons.com
09:15AM  AUDENTES THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
08:26AM  Astellas bets $3 billion in gene therapy deal MarketWatch
07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
06:09AM  [video]Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase TheStreet.com
Dec-02-19 11:10PM  Audentes Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Audentes Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm BOLD GlobeNewswire
06:01PM  Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics Business Wire
Nov-26-19 04:01PM  Audentes Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Nov-21-19 04:54AM  Edited Transcript of BOLD earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-19 04:01PM  Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Oct-31-19 07:00AM  Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019 Business Wire
Oct-25-19 10:01AM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
Oct-05-19 07:01AM  Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society Business Wire
Oct-04-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
01:30AM  Edited Transcript of BOLD earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-01-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences Business Wire -6.19%
Sep-30-19 08:00AM  Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM) Business Wire
Sep-19-19 09:59AM  Have Insiders Been Selling Audentes Therapeutics, Inc. (NASDAQ:BOLD) Shares? Simply Wall St. +5.31%
Sep-06-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-26-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Aug-20-19 12:02PM  Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:03AM  Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Aug-19-19 08:58AM  Solid Biosciences Surges on DMD Gene Therapy Study Amendments Zacks
Aug-06-19 11:24PM  Audentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Call Transcript Motley Fool
04:01PM  Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
Aug-01-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Jul-30-19 08:00AM  Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019 PR Newswire
Jul-19-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-09-19 09:56AM  How Does Investing In Audentes Therapeutics, Inc. (NASDAQ:BOLD) Impact The Volatility Of Your Portfolio? Simply Wall St.
Jun-19-19 10:41AM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
Jun-07-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +6.68%
May-29-19 04:01PM  Audentes Therapeutics Announces Changes to Senior Management Team PR Newswire
May-15-19 04:45AM  Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 09:23AM  Audentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript Motley Fool
08:00AM  Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference PR Newswire
May-07-19 04:32PM  Audentes Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
May-02-19 01:53PM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
May-01-19 02:15PM  Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy PR Newswire
Apr-30-19 08:00AM  Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019 PR Newswire
Apr-26-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-23-19 08:00AM  Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility PR Newswire
Apr-22-19 02:39PM  Estimating The Fair Value Of Audentes Therapeutics, Inc. (NASDAQ:BOLD) Simply Wall St.
Apr-15-19 04:01PM  Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
07:00AM  Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy PR Newswire
Apr-05-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soloway Thomas PExecutive Vice President, CFOJan 08Option Exercise3.28150,888494,897183,384Jan 10 06:19 PM
Patterson Matthew RChief Executive OfficerJan 08Option Exercise3.10162,538503,567261,458Jan 10 06:18 PM
LANGE LOUIS GDirectorDec 23Sale59.601,00059,59613,678Dec 27 04:10 PM
LANGE LOUIS GDirectorDec 23Sale59.6010,000595,993265,799Dec 27 04:10 PM
Soloway Thomas PExecutive Vice President, CFODec 12Option Exercise2.7641,321114,24853,954Dec 16 06:05 PM
Holles Natalie C.President and COODec 12Option Exercise12.68147,3441,868,986193,367Dec 16 06:03 PM
Patterson Matthew RChief Executive OfficerNov 08Option Exercise9.5014,426137,047127,820Nov 12 05:32 PM
Patterson Matthew RChief Executive OfficerNov 08Sale30.0014,426432,780113,394Nov 12 05:32 PM
LANGE LOUIS GDirectorSep 23Sale32.181,00032,18214,678Sep 25 06:11 PM
LANGE LOUIS GDirectorSep 23Sale32.1610,000321,616275,799Sep 25 06:11 PM
Patterson Matthew RChief Executive OfficerAug 12Option Exercise9.5020,000190,000135,368Aug 14 07:03 PM
Patterson Matthew RChief Executive OfficerAug 12Sale34.0420,000680,835115,368Aug 14 07:03 PM
LANGE LOUIS GDirectorJun 24Sale38.201,00038,20115,678Jun 26 04:07 PM
LANGE LOUIS GDirectorJun 24Sale37.7720,000755,413285,799Jun 26 04:07 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMay 13Option Exercise0.7910,0007,90028,236May 15 04:42 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMay 13Sale36.9810,000369,79818,236May 15 04:42 PM
LANGE LOUIS GDirectorMar 25Sale35.981,55856,0580Mar 27 05:03 PM
LANGE LOUIS GDirectorMar 25Sale36.0020,000720,015305,799Mar 27 05:03 PM
Patterson Matthew RChief Executive OfficerFeb 25Option Exercise1.0521,00022,020135,700Feb 27 04:31 PM
PRASAD SUYASHSenior VP & Chief Med OfficerFeb 25Option Exercise0.7910,0007,90028,236Feb 27 04:32 PM
PRASAD SUYASHSenior VP & Chief Med OfficerFeb 25Sale30.0610,000300,55318,236Feb 27 04:32 PM
Patterson Matthew RChief Executive OfficerFeb 25Sale30.0021,000630,000118,700Feb 27 04:31 PM
Holles Natalie C.President and COOJan 24Option Exercise2.768,30022,94933,390Jan 25 07:28 PM